Coexistent hairy cell leukaemia and hepatosplenic t-cell lymphoma: a case report
© Gasljevic et al.; licensee BioMed Central Ltd. 2014
Received: 15 December 2013
Accepted: 3 March 2014
Published: 12 March 2014
Hairy cell leukaemia (HCL) is a chronic B-cell leukaemia characterized by expansion of neoplastic cells in the spleen, bone marrow and blood. Symptoms of HCL are related to pancytopenia and immune deficiency. Patients with HCL have an increased risk of second malignancy either in a form of synchronous disease or in a form of an increased incidence of a second neoplasm after the treatment of HCL. Hepatosplenic T-cell lymphoma (HSTCL) is a rare form of aggressive extranodal T-cell lymphoma. Its pathogenesis is connected to a chronic immune deficiency status and its coexistence with other neoplasms is practically non-existent.
We present a case of a 53-year-old female patient suffering from hepatosplenomegaly, peripheral lymphadenopathy and related B symptoms. An excisional biopsy of the enlarged axillary lymph node revealed partial infiltration with CD3+/CD56+/TIA + T cell lymphoma. Bone marrow trephine biopsy and flow cytometric immunophenotypization of bone marrow cells and peripheral blood showed presence of two types of neoplastic cells in the peripheral blood and in the bone marrow (composite lymphoma). One of them showed typical morphologic characteristics and immunohistochemical features of HCL, while another one was morphologically and immunophenotypically consistent with the diagnosis of HSTCL, respectively. The patient was treated with multivalent chemotherapy including rituximab but all treatments turned out to be only partially effective. While HCL responded to the treatment, HSTCL was refractory to the chemotherapy and the patient died 7 months after the initial diagnosis because of haematemesis induced by Mallory-Weiss syndrome.
This is the first recorded case of coexistent HCL and HSTCL in the same patient. A multidisciplinary approach, encompassing careful morphology interpretation, immunophenotypic, cytogenetic and molecular analyses, is mandatory to obtain an accurate diagnosis of composite lymphoma.
The virtual slides for this article can be found here: http://www.diagnosticpathology.diagnomx.eu/vs/9354870531161685.
KeywordsHairy cell leukemia Hepatosplenic γɗ T cell lymphoma Coexistency Flow cytometric immunophenotyping
Hairy cell leukaemia (HCL) is a chronic B-cell leukaemia characterised by pancytopenia and clonal expansion of mature malignant B cells in the spleen, bone marrow and blood . Characteristically, patients with HCL do not suffer from leukaemia itself but from symptoms that are related to pancytopenia and opportunistic infections . Hepatosplenic T-cell lymphoma (HSTCL) is a rare form of extranodal T-cell lymphoma derived from cytotoxic T cells. In up to 20% of cases, its pathogenesis is connected to a chronic immune deficiency status, such as prolonged immunosuppressive therapy after organ transplantation, long-term combined therapy with thiopurines and anti-TNF agents for chronic inflammatory bowel diseases or prolonged antigen stimulation [1, 3]. Both diseases demonstrate propensity to infiltrate the spleen, liver and bone marrow. Their coexistence has to be exceptional because we have found no reports about concurrent occurrence of HCL and HSTCL in the English literature by now. The objective of this study is to report the clinical and pathological features of a 53-year-old female patient with coexistent HCL and HSTCL who was recently treated at our institution.
A 53-year-old female was referred to our centre because of a two-month lasting exhaustion, abdominal distension, early satiety and fever of up to 39°C. Her medical history was not significant. She had been travelling for a longer periods of time in the countries of the Middle and Far East, especially to Indochina and India. Physical examination showed splenomegaly and hepatomegaly, palpable at 15 and 6 cm below the costal margin, respectively. Peripheral lymph nodes measured up to 1 cm in the largest diameter. Petechiae and suffusions were present on the skin of the thoracic region and flanks. Laboratory tests demonstrated: (1) white blood count 3.40 × 109/l (Neu 2,01 (59%) , Ly 0,99 (29%), Mono 0,17 (5%), Eos 0,03 (1%)), platelet count 64 × 109/l, red blood cells 3,66 × 109/l, haemoglobin level 115 g/l (2) liver function tests were raised: AST 2.21 IU/L, ALT 0.95 IU/L and γGT 1.30 IU/L with bilirubin within normal ranges-bilirubin 17 IU/L (3) LDH was raised to 15,68 IU/L; raised was also CRP to 35 (4) serology for HAV showed reactive IgG anti-HAV antibodies, whereas IgM anti-HAV, HbsAg, anti- HBc, anti-Hbs, anti-HCV and CMV were negative.
HCL is an uncommon form of chronic lymphoproliferative disease, characterised by indolent course. Hairy cells typically home to the spleen and circulate only late in the disease. Their proliferation is regulated by different cytokines and growth factors in an autocrine and paracrine fashion . Many manifestations seen in the peripheral blood in patients with HCL are the result of interactions between the neoplastic B cells and the T-cell system. Among others, there are profound alterations in the T-cell immunity with the production of a skewed T-cell repertoire , production of autoreactive T cells, and an increase in the CD3 + γδ cells as a persistent clonal excess, as well as monocytopenia, leucopenia, and so on . All of the above-mentioned factors contribute significantly to the immune deficiency found in HCL patients and to the extreme sensitivity to opportunistic infections.
Since all of the above-listed factors play important roles also in the surveillance against neoplasia, it is likely that the appearance of the second neoplasms in HCL reflects an underlying immune deficiency in such patients rather than random coexistence of the two diseases. Some studies showed that patients with HCL have an increased risk of second malignancy, either in a form of synchronous disease [7–10] or in a form of an increased incidence of a second neoplasm after the treatment of HCL [11–13]. Among malignancies with synchronous occurrence, the most frequent is the occurrence with other haematopoietic malignancies [14–21], B-cell lymphomas in the first place, and very rarely also with T-cell neoplasms. Contemporary literature provides only rare case reports describing the coexistence of HCL with LGL leukaemia  and simultaneous presentation of HCL and peripheral T-cell lymphoma .
On the other hand, HSTCL is a rare and very aggressive form of extranodal lymphoma with a median survival of less than 2 years, despite therapy . Its coexistence with other haematologic malignancies is practically non-existent, which could be a result of its aggressive nature and the usually quick lethal outcome. In the recent literature, there are only two case reports of HSTCL that presented together with some other type of haematologic disease. One is a case of coexistence with aggressive CD56+ CD3- TcRγδ- leukaemia , and the other is HSTCL in conjunction with systemic mastocytosis .
However, coexistence of two or more morphologically and immunophenotypically distinct lymphoma clones in a single anatomic site is nowadays defined as composite lymphoma . The incidence of composite lymphoma has been reported to vary between 1% and 4.7% . Many different combinations of composite lymphomas have been described . The diagnosis of composite T-cell and B-cell lymphomas is particularly challenging because the neoplastic T-cells may outnumber the neoplastic B-cells, occasionally creating a false impression that B-cells are reactive. Similarly, the neoplastic B-cells may also outnumber the neoplastic T-cells, which may result in overlooking the T-cell lymphoma. A multidisciplinary approach, encompassing immunophenotypic, cytogenetic and molecular analyses, is therefore mandatory to obtain an accurate diagnosis. FCI can be very helpful in these settings, because it can detect small populations of neoplastic B-cells or T-cells, which could be overlooked in morphological and immunohistochemical analyses .
Any lymphoproliferative disease infiltrating spleen and liver can mimic HSTCL or HCL. Detailed study of morphology, together with immunophenotyping, gene rearrangement analyses, determining of EBV status and cytogenetic studies could help to establish the right diagnosis [27–32]. Two diseases that show great overlapping with HSTCL regarding clinical picture as well as immunophenotype are aggressive NK-cell leukaemia and advanced extranodal NK/T-cell lymphoma, nasal type. Although immunophenotype could overlap significantly, rearranged TCR gene and no relation to EBV infection are distinguishing features that speak in the favour of the HSTCL [27–29]. HCL can be distinguish from other B-cell neoplasms by its morphology and characteristic immunophenotype, while presence of B symptoms, organomegaly and signs of infection exclude the diagnosis of monoclonal B lymphocytosis with HCL-like phenotype in our patient .
In an attempt to explain the coexistence of HCL and HSTCL in our patient, some hypotheses can be formulated. Simultaneous appearance of HCL and HSTCL in our patient could be only fortuitous. However, since HSTCL often arises in the setting of chronic immune suppression, and HCL is a malignancy with a proven profound immune deficiency, their random coexistence is less likely. If persistent clonal excess of T-lymphocytes and skewed T-cell repertoires found in HCL are the only factors that could influence the course of T-cell oncogenesis in HCL patients, one could expect a much higher incidence of synchronous occurrence of HCL and T-cell lymphoma.
In conclusion, hereby, we present the first case of coexistent HCL and HSTL that has been, to the best of our knowledge, described in the English literature so far.
Written informed consent was obtained from the patient’s parent for the publication of this report and any accompanying images.
Hairy cell leukemia
Hepatosplenic T cell lymphoma
Fine needle aspiration biopsy
Flow cytometric immunophenotyping
Rituximab-vincristine, doxorubicin, cyclophosphamide, prednisone, etoposide
Rituximab, dexamethasone, cytarabine , cisplatin
Rituximab- etoposide, vincristine, doxorubicin, cyclophosphamide, prednisone.
- Jaffe ES, Ralfkiaer E: Hepatosplenic T cell lymphoma, hairy cell leukemia. WHO Classification of Tumours of Haematopoietic and Lymphoid Tissue. Edited by: Swerdlow S, Campo E, Lee Harris N, Jaffe ES, Pileri SA, Stein H, Thiele J, Vardiman JW. 2008, Lyon: IARCGoogle Scholar
- Polliack A: Hairy cell leukemia: biology, clinical diagnosis, unusual manifestations and associated disorders. Rev Clin Exp Hematol. 2002, 6: 366-387.PubMedView ArticleGoogle Scholar
- Kotlyar DS, Osterman MT, Diamond RH, Porter D, Blonski WC, Wasik M, Sampat S, Mendizabal M, Lin MV, Lichtenstein GR: A systematic review of factors that contribute to hepatosplenic T cell lymphoma in patients with inflammatory bowel disease. Clin Gastroent Hepat. 2011, 9: 36-41. 10.1016/j.cgh.2010.09.016.View ArticleGoogle Scholar
- Schmid M, Porzsolt F: Autocrine and paracrine regulation of neoplastic cell growth in hairy cell leukemia. Leuk Lymph. 1995, 17: 401-410. 10.3109/10428199509056850.View ArticleGoogle Scholar
- Kluin-Nelemans JC, Kester MG, Melenhorst JJ, Landegent JE, van der Corput L, Willemze R, Falkenburg JH: Persistent clonal excess and skewed T-cell repertoire in T cells from patients with hairy cell leukemia. Blood. 1996, 87: 3795-3802.PubMedGoogle Scholar
- Bourguin-Plonquet A, Rouard H, Roudot-Thoraval F, Bellanger C, Marquet J, Delfau-Larue MH, Divine M, Farcet JP: Severe decrease in peripheral blood dendritic cells in hairy cell leukemia. Br J Haematol. 2002, 16: 595-597.View ArticleGoogle Scholar
- Kurzrock R, Strom SS, Estey E, O’Brien S, Keating MJ, Jiang H, Adams T, Talpaz M: Second cancer risk in hairy cell leukemia: analysis of 350 patients. J Clin Oncol. 1803–1810, 1997: 15-Google Scholar
- Aydin SO, Eskazan AE, Aki H, Ozguroglu M, Baslar Z, Soysal T: Synchronous detection of hairy cell leukemia and HIV negative Kaposi’s sarcoma of the lymph node: a diagnostic challenge and a rare coincidence. Case Rep Oncol. 2011, 4: 439-444. 10.1159/000331894.PubMedPubMed CentralView ArticleGoogle Scholar
- Laurent G: Neoplasm associated with hairy cell leukemia. Acta Hemat. 1982, 69: 142-View ArticleGoogle Scholar
- Nielsen B, Braide I, Hesselbach H: Evidence for an association between hairy cell leukemia and renal cell carcinoma. Cancer. 2087–2090, 1992: 70-Google Scholar
- Hisada M, Chen BE, Jaffe ES, Travis LB: Second cancer incidence and cause-specific mortality among 3104 patients with hairy cell leukemia: a population-based study. JNCI. 2007, 3: 215-View ArticleGoogle Scholar
- Kampmeier P, Spielberger R, Dickstein J, Mick R, Golomb H, Vardiman J: Increased incidence of second neoplasms in patients treated with interferon alpha 2b for hairy cell leukemia: a clinicopathological assessment. Blood. 1994, 83: 2931-2938.PubMedGoogle Scholar
- Au WY, Klasa RJ, Gallagher R, Le N, Gascoyne RD, Conners JM: Second malignancies in patients with hairy cell leukemia in British Columbia: a 20-year experience. Blood. 1998, 92: 1160-1164.PubMedGoogle Scholar
- Saif MW, Greenberg BR: Multiple myeloma and hairy cell leukemia: a rare association or coincidence?. Leuk Lymphoma. 2001, 5: 1043-1048.View ArticleGoogle Scholar
- Brown SA, Phillips J, Ahsan G, Slater NG: Coexistent hairy cell leukemia and chronic lymphocytic leukemia. Leuk Lymphoma. 1998, 1: 203-209.Google Scholar
- Sokol L, Agosti SJ: Simultaneous manifestation of chronic lymphocytic leukemia (CLL) and hairy cell leukemia (HCL). Am J Hematol. 2004, 75: 107-109. 10.1002/ajh.10459.PubMedView ArticleGoogle Scholar
- Giné E, Bosch F, Villamor N, Rozman M, Colomer D, Lopez-Guillermo A, Campo E, Montserrat E: Simultaneous diagnosis of hairy cell leukemia and chronic lymphocytic leukemia/small lymphocytic lymphoma: a frequent association?. Leukemia. 2002, 16: 1454-1459. 10.1038/sj.leu.2402553.PubMedView ArticleGoogle Scholar
- Pajor L, Kereskai L, Tamaska P, Vass JA, Radvanyi G: Coexistence of chronic myeloid leukemia and hairy cell leukemia of common clonal origin. Canc Gen Cytogen. 2002, 134: 114-117. 10.1016/S0165-4608(01)00632-X.View ArticleGoogle Scholar
- Lawlor E, O’Brian S, Finn T, Ward R, Rogers F, O’Brien AA, Daly PA: The simultaneous presentation of peripheral T-cell lymphoma and hairy cell leukemia. Cancer. 1987, 60: 1537-10.1002/1097-0142(19871001)60:7<1537::AID-CNCR2820600721>3.0.CO;2-S.PubMedView ArticleGoogle Scholar
- Marolleau JP, Henni T, Gaulard P, Le Couedic JP, Gourdin MF, Divine M, Katz A, Tulliez M, Goossens M, Reyes F: Hairy cell leukemia associated with large granular lymphocyte leukemia: immunologic and genomic study, effect of interferon treatment. Blood. 1988, 72 (2): 655-660.PubMedGoogle Scholar
- Resegotti L, Pistone M, Testa D, Ruà S, Coda R: Simultaneous occurrence of hairy cell leukemia and Hodgkin’s disease in the same patient. Haematologica. 1985, 70: 185-PubMedGoogle Scholar
- Camera A, Pezzullo L, Villa MR, Luciano L, Pane F, Izzo B, Boccuni P, Di Noto R, Del Vecchio L, Salvatore F, Rotoli B: Coexistence of two distinct cell populations (CD56 + TcRγδ + and CD56+ TcRγδ-) in a case of aggressive CD56+ lymphoma/leukemia. Haematologica. 2000, 85: 496-PubMedGoogle Scholar
- Perini G, Pro B: Hepatosplenic gamma-delta T cell lymphoma disseminated intravascular coagulation and systemic mastocytosis: an unusual presentation for a rare disease. Clin Adv Hemat Oncol. 2010, 10: 693-694.Google Scholar
- Mokhtar NM: Review article: composite lymphoma. NAtl Canc Inst. 2007, 19: 171-175.Google Scholar
- Kim H: Composite lymphoma and related disorders. Am J Clin Pathol. 1993, 99: 445-451.PubMedGoogle Scholar
- Demurtus A, Aliberti S, Bonello L, Di Celle PF, Cavaliere C, Barreca A, Nover D, Stacchini A: Usefulness of multiparametric flow cytometry in detecting composite LymphomaStudy of 17 cases in a 12-year period. Am J Clin Pathol. 2011, 135: 541-55. 10.1309/AJCPQKE25ADCFZWN.View ArticleGoogle Scholar
- Gao L, Liu W, Yang Q, Li H, Chen J, Tang Y, Zou Y, Liao DY, Liu Y, Zhao S: Aggressive natural-killer leukemia with jaundice and spontaneous splenic rupture: a case report and review of the literature. Diagn Pathol. 2013, 8: 43-10.1186/1746-1596-8-43.PubMedPubMed CentralView ArticleGoogle Scholar
- Gong L, Wei LX, Huang GS, Zhang WD, Wang L, Zhu SJ, Han XJ, Yao L, Lan M, Li YH, Zhang W: Identification of genuine primary pulmonary NK cell lymphoma via clinicopathologic observation and clonality assay. Diagn Pathol. 2001, 8: 140-View ArticleGoogle Scholar
- Pongpruttipan T, Kummalue T, Bedavanija A, Khuhapinant A, Oshshima K, Arakawa F, Niino D, Suchpanichnant S: Aberrant antigenic expression in extranodal NK/T-cell lymphoma: a multiparameter study from Thailand. Diagn Pathol. 2011, 6: 79-10.1186/1746-1596-6-79.PubMedPubMed CentralView ArticleGoogle Scholar
- Chang H, Chuang WY, Sun CF, Barnard MR: Concurrent acute myeloid leukemia and T lymphoblastic lymphoma in a patient with rearranged PDGFRB genes. Diagnstic Pathol. 2012, 7: 19-10.1186/1746-1596-7-19.View ArticleGoogle Scholar
- Gonzalez-Cuyar LF, Tavora F, Zhao XF, Wang G, Auerbach A, Aguilera N, Burke AP: Angiolymphoid hyperplasia with eosinophilia developing in a patient with history of peripheral T cell lymphoma: evidence for multicentric T-cell lymphproliferative process. Diagn Pathol. 2008, 3: 22-10.1186/1746-1596-3-22.PubMedPubMed CentralView ArticleGoogle Scholar
- Aquino G, Franco R, Ronconi F, Anniciello A, Russo L, De Chiara A, Panico L: Peripheral T-cell lymphoma with cycline D1 overexpression: a case report. Diagn Pathol. 2012, 7: 79-10.1186/1746-1596-7-79.PubMedPubMed CentralView ArticleGoogle Scholar
- Marti GE, Rawstron AC, Ghia P, Hillmen P, Houlston RS, Kay N, Schleinitz TA, Caporaso N: Diagnostic criteria for monoclonal B-cell lymphocytosis. Br J Haematol. 2005, 130: 325-10.1111/j.1365-2141.2005.05550.x.PubMedView ArticleGoogle Scholar
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.